Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.

NCT00699517 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00699517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00699517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Randomized, Double-blind Placebo Controlled Study of AVE8062 (25 mg/m2) Administered Every 3 Weeks in Patients With Advanced-stage Soft Tissue Sarcoma, Treated With Cisplatin (75 mg) After Failure of Anthracycline and Ifosfamide Chemotherapies.
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2008
Completion date
April 30, 2013
Enrollment
355 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma